{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:29:50Z","timestamp":1786480190749,"version":"build-2736575974"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2020,5]]},"abstract":"\n Background<\/jats:title>\n \n There is no consensus regarding dose and frequency of rituximab in nephrology with extrapolation of doses used in treating lymphoproliferative disorders. There are no guidelines on targeting initial and subsequent doses on the basis of CD19\n +<\/jats:sup>\n B cells.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Initially, 100 mg rituximab was given to 42 adults with steroid-dependent nephrotic syndrome (SDNS) and frequently relapsing nephrotic syndrome (FRNS), idiopathic membranous nephropathy (MN), and high-immunologic-risk kidney transplantation. Absolute and percentage levels of CD19 B cells and clinical status were assessed at baseline, days 30, 90, and 180, and at 1 year. Subsequent doses of rituximab were on the basis of CD19 B cell reconstitution and clinical response.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n CD19 B cell percentage decreased from 16.3 \u00b1 7.6 to 0.3 \u00b1 0.3 (\n P<\/jats:italic>\n \u22640.001), 1.9 \u00b1 1.7 (\n P<\/jats:italic>\n \u22640.001), and 4.0 \u00b1 4.5 (\n P<\/jats:italic>\n =0.005) by 30, 90, and 180 days, respectively. Suppression of CD19 B cell count below 1% at days 30, 90, and 180 was seen in 40 of 42 (95.2%), 18 of 42 (42.9%), and 7 of 42 (16.7%) patients, respectively. Of 30 with SDNS and FRNS followed up for 1 year, 29 (96.7%) went into remission at day 30. Remission was sustained in 23 (76.6%) at day 180 and 21 (70%) at 1 year. There was a significant decrease (\n P<\/jats:italic>\n <0.001) in the dose of steroids needed to maintain remission at 180 days after rituximab (0.27 \u00b1 0.02 mg\/kg to 0.02 \u00b1 0.00 mg\/kg). CD19 B cell percentage at 90 days correlated with relapse (\n P<\/jats:italic>\n =0.001; odds ratio 1.42; 95% confidence interval, 1.25 to 2.57). Eighteen (60%) required an additional dose. Of five with MN, four achieved remission by 6 months, which was sustained in three by 1 year. Of the seven kidney transplant recipients, two had antibody-mediated rejections, although CD19 B cells were suppressed even at 1 year.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Low-dose rituximab induces sustained depletion of CD19 B cells for up to 90 days. Its role in preventing relapses in SDNS, FRNS, MN, and rejection needs further study.<\/jats:p>\n <\/jats:sec>","DOI":"10.34067\/kid.0000072020","type":"journal-article","created":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T18:25:15Z","timestamp":1585851915000},"page":"359-367","source":"Crossref","is-referenced-by-count":11,"title":["Clinical Response and Pattern of B cell Suppression with Single Low Dose Rituximab in Nephrology"],"prefix":"10.34067","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6592-3215","authenticated-orcid":false,"given":"Jacob","family":"George","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunu","family":"Alex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.T. Arun","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noble","family":"Gracious","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nalanda S.","family":"Vineetha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajeev","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,5,28]]},"reference":[{"key":"B1-20230821","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"B2-20230821","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMra0708875","article-title":"Monoclonal antibody therapy for B-cell non-Hodgkin\u2019s lymphoma","volume":"359","author":"Cheson","year":"2008","journal-title":"N Engl J Med"},{"key":"B3-20230821","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.autrev.2011.11.007","article-title":"B-cell depleting agents for ANCA vasculitides: A new therapeutic approach","volume":"11","author":"G\u00f3mez-Puerta","year":"2012","journal-title":"Autoimmun Rev"},{"key":"B4-20230821","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1002\/art.22046","article-title":"Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment","volume":"54","author":"Smith","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B5-20230821","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1053\/j.ajkd.2006.10.015","article-title":"Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: First case report and pathophysiological considerations","volume":"49","author":"Fran\u00e7ois","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"B6-20230821","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1007\/s00467-004-1434-z","article-title":"Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy","volume":"19","author":"Benz","year":"2004","journal-title":"Pediatr Nephrol"},{"key":"B7-20230821","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","article-title":"Rituximab for idiopathic membranous nephropathy","volume":"360","author":"Remuzzi","year":"2002","journal-title":"Lancet"},{"key":"B8-20230821","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ajt.13052","article-title":"Rituximab as induction therapy after renal transplantation: A randomized, double-blind, placebo-controlled study of efficacy and safety","volume":"15","author":"van den Hoogen","year":"2015","journal-title":"Am J Transplant"},{"key":"B9-20230821","first-page":"306","article-title":"Unexpected and persistent depletion of B lymphocytes CD20 following a minimum dose of anti-CD20 antibody (Rituximab)","volume":"61","author":"Bruzzese","year":"2009","journal-title":"Reumatismo"},{"key":"B10-20230821","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1212\/01.wnl.0000267325.06000.d9","article-title":"Progressive multifocal leukoencephalopathy after rituximab in a case of non-Hodgkin lymphoma","volume":"69","author":"Kranick","year":"2007","journal-title":"Neurology"},{"key":"B11-20230821","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/cei.12481","article-title":"Usefulness of monitoring of B cell depletion in rituximab-treated rheumatoid arthritis patients in order to predict clinical relapse: A prospective observational study","volume":"180","author":"Trouvin","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"B12-20230821","doi-asserted-by":"crossref","first-page":"738","DOI":"10.2215\/CJN.01080905","article-title":"Rituximab for idiopathic membranous nephropathy: Who can benefit?","volume":"1","author":"Ruggenenti","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"B13-20230821","doi-asserted-by":"crossref","first-page":"932","DOI":"10.2215\/CJN.01180307","article-title":"Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy","volume":"2","author":"Cravedi","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"B14-20230821","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"B15-20230821","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: A 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B16-20230821","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2215\/CJN.11791018","article-title":"High-dose rituximab and early remission in PLA2R1-related membranous nephropathy","volume":"14","author":"Seitz-Polski","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"B17-20230821","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.2215\/CJN.05080610","article-title":"Rituximab therapy in idiopathic membranous nephropathy: A 2-year study","volume":"5","author":"Fervenza","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"B18-20230821","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/ckj\/sfy067","article-title":"Continuous B-cell depletion in frequently relapsing, steroid-dependent and steroid-resistant nephrotic syndrome","volume":"12","author":"Cortazar","year":"2018","journal-title":"Clin Kidney J"},{"key":"B19-20230821","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1681\/ASN.2014080799","article-title":"Rituximab in children with steroid-dependent nephrotic syndrome: A multicenter, open-label, noninferiority, randomized controlled trial","volume":"26","author":"Ravani","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B20-20230821","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1007\/s00467-017-3718-0","article-title":"Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab","volume":"32","author":"Kamei","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"B21-20230821","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1681\/ASN.2013030251","article-title":"Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome","volume":"25","author":"Ruggenenti","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B22-20230821","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2215\/CJN.00570109","article-title":"Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis","volume":"4","author":"Fernandez-Fresnedo","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"B23-20230821","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/ki.2012.444","article-title":"Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease","volume":"83","author":"Munyentwali","year":"2013","journal-title":"Kidney Int"},{"key":"B24-20230821","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10157-015-1139-6","article-title":"Amelioration of the adverse effects of prednisolone by rituximab treatment in adults with steroid-dependent minimal-change nephrotic syndrome","volume":"20","author":"Miyabe","year":"2016","journal-title":"Clin Exp Nephrol"},{"key":"B25-20230821","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1681\/ASN.2015050523","article-title":"B cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome","volume":"27","author":"Colucci","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B26-20230821","doi-asserted-by":"crossref","first-page":"85ra46","DOI":"10.1126\/scitranslmed.3002231","article-title":"Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis","volume":"3","author":"Fornoni","year":"2011","journal-title":"Sci Transl Med"},{"key":"B27-20230821","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1681\/ASN.2014070640","article-title":"Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy","volume":"26","author":"Ruggenenti","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B28-20230821","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1681\/ASN.2010111125","article-title":"Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy","volume":"22","author":"Beck","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"B29-20230821","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.2215\/CJN.07300619","article-title":"Does epitope spreading influence Responsiveness to rituximab in PLA2R-associated membranous nephropathy?","volume":"14","author":"Salant","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"B30-20230821","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1681\/ASN.2014111061","article-title":"Epitope spreading of autoantibody response to PLA2R associates with poor prognosis in membranous nephropathy","volume":"27","author":"Seitz-Polski","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B31-20230821","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ekir.2016.08.019","article-title":"CD19 targeted low-dose rituximab is effective in the management of refractory phospholipase A2 receptor antibody-associated membranous nephropathy","volume":"2","author":"Ramachandran","year":"2016","journal-title":"Kidney Int Rep"},{"key":"B32-20230821","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa0707894","article-title":"Rituximab and intravenous immune globulin for desensitization during renal transplantation","volume":"359","author":"Vo","year":"2008","journal-title":"N Engl J Med"},{"key":"B33-20230821","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1097\/TP.0b013e3181a235fd","article-title":"A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation","volume":"87","author":"Tyd\u00e9n","year":"2009","journal-title":"Transplantation"},{"key":"B34-20230821","doi-asserted-by":"crossref","first-page":"e475","DOI":"10.1097\/TXD.0000000000000923","article-title":"Low-dose rituximab and thymoglobulin induction with steroid-free maintenance immunosuppression and protocol biopsies improves long-term patient and Graft Survival after kidney transplantation: Survival and safety outcomes in more than 1100 patients from a single center","volume":"5","author":"Pathak","year":"2019","journal-title":"Transplant Direct"},{"key":"B35-20230821","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/TP.0000000000001849","article-title":"Anti-CD20 blocker rituximab in kidney transplantation","volume":"102","author":"Sood","year":"2018","journal-title":"Transplantation"},{"key":"B36-20230821","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1097\/00007890-200211150-00001","article-title":"Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis","volume":"74","author":"Sawada","year":"2002","journal-title":"Transplantation"},{"key":"B37-20230821","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.transproceed.2013.09.036","article-title":"Outcome comparison of ABO-incompatible kidney transplantation with low-dose rituximab and ABO-compatible kidney transplantation: A single-center experience","volume":"46","author":"Hatakeyama","year":"2014","journal-title":"Transplant Proc"},{"key":"B38-20230821","doi-asserted-by":"crossref","first-page":"126","DOI":"10.21037\/tau.2019.03.05","article-title":"Current protocols and outcomes of ABO-incompatible kidney transplantation based on a single-center experience","volume":"8","author":"Okumi","year":"2019","journal-title":"Transl Androl Urol"},{"key":"B39-20230821","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B40-20230821","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/ndt\/gfs285","article-title":"Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis","volume":"28","author":"Weidenbusch","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"B41-20230821","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"B42-20230821","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","article-title":"Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: Results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)","volume":"77","author":"Charles","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B43-20230821","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s10067-019-04443-2","article-title":"Low-dose rituximab as induction therapy for ANCA-associated vasculitis","volume":"38","author":"Takakuwa","year":"2019","journal-title":"Clin Rheumatol"},{"key":"B44-20230821","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00467-018-4052-x","article-title":"Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome","volume":"34","author":"Hogan","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"B45-20230821","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00467-018-4172-3","article-title":"Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome","volume":"34","author":"Maxted","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"B46-20230821","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/ajt.12220","article-title":"A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function","volume":"13","author":"Kamburova","year":"2013","journal-title":"Am J Transplant"},{"key":"B47-20230821","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/art.10764","article-title":"The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus","volume":"48","author":"Anolik","year":"2003","journal-title":"Arthritis Rheum"},{"key":"B48-20230821","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s00467-014-2794-7","article-title":"Development of antirituximab antibodies in children with nephrotic syndrome","volume":"29","author":"Ahn","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"B49-20230821","doi-asserted-by":"crossref","first-page":"15629","DOI":"10.1038\/s41598-018-34111-5","article-title":"Effects of rituximab dose on hepatitis B reactivation in patients with resolved infection undergoing immunologic incompatible kidney transplantation","volume":"8","author":"Lee","year":"2018","journal-title":"Sci Rep"}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000072020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T19:56:44Z","timestamp":1786478204000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000072020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0000072020","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}